Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Cardiology Update from the 2008 ACC Annual Meeting
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Overview
Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
Level Up Your Skills: Tailoring Management of HF
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?